Cellular rejuvenation and anti-aging
Rējen™ is positioned as a cellular rejuvenation ingredient targeting multiple hallmarks of aging — cellular senescence accumulation, impaired autophagy, mitochondrial dysfunction, and epigenetic drift. As a newly launched ingredient (late 2025), clinical evidence is in early stages with preclinical mechanistic data supporting the rejuvenation concept.
Longevity pathway activation
Based on Compound Solutions' stated positioning, Rējen™ targets longevity signaling pathways associated with healthspan extension — including autophagy induction, SIRT1/AMPK activation, and reduction of pro-aging inflammatory signals. The ingredient fits within the growing category of senolytic and autophagy-enhancing compounds alongside fisetin, urolithin A, and spermidine.
Multi-hallmark aging intervention
Rējen™ is designed to address multiple hallmarks of aging simultaneously — the approach supported by longevity research showing that interventions targeting single pathways have modest effects, while multi-target approaches addressing cellular senescence, proteostasis, mitochondrial dysfunction, and epigenetic alterations produce more robust healthspan extension. Specific mechanistic details pending full ingredient disclosure.
Newly launched ingredient (late 2025). Clinical trials underway per Compound Solutions.
Clinical study data not yet published.
Preclinical mechanistic data supporting cellular rejuvenation activity. Human clinical trials in progress. Early-adopter evidence being compiled. Check compoundsolutions.com for latest research updates.